Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA. Medicherla S, et al. Among authors: dugar s. J Pharmacol Exp Ther. 2006 Jul;318(1):132-41. doi: 10.1124/jpet.105.098020. Epub 2006 Apr 5. J Pharmacol Exp Ther. 2006. PMID: 16597712
Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.
Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF. Medicherla S, et al. Among authors: dugar s. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. doi: 10.1124/jpet.105.097857. Epub 2006 Apr 7. J Pharmacol Exp Ther. 2006. PMID: 16603672
Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.
Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS. Kapoun AM, et al. Among authors: dugar s. Mol Pharmacol. 2006 Aug;70(2):518-31. doi: 10.1124/mol.105.021600. Epub 2006 May 17. Mol Pharmacol. 2006. PMID: 16707625
Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase.
Koppelman B, Webb HK, Medicherla S, Almirez R, Feng Y, Chavez JC, Mao CP, Nguyen A, Liu YW, Kapoun AM, Muiru G, Huang YA, Dugar S, Mavunkel BJ, Lim DW, Chakravarty S, Luedtke G, Protter AA, Higgins LS. Koppelman B, et al. Among authors: dugar s. Pharmacology. 2008;81(3):204-20. doi: 10.1159/000112865. Epub 2008 Jan 7. Pharmacology. 2008. PMID: 18176091
Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain.
Svensson CI, Medicherla S, Malkmus S, Jiang Y, Ma JY, Kerr I, Brainin-Mattos J, Powell HC, Luo ZD, Chakravarty S, Dugar S, Higgins LS, Protter AA, Yaksh TL. Svensson CI, et al. Among authors: dugar s. Pharmacol Biochem Behav. 2008 Oct;90(4):664-75. doi: 10.1016/j.pbb.2008.05.016. Pharmacol Biochem Behav. 2008. PMID: 18584857
151 results